

Our Ref: 98
February 2024

Re: Your request made under the Freedom of Information Act 2000

I am analysing the usage of new biologic and targeted medications within dermatology and respiratory medicine. Could you please answer the following questions:

Q1. How many patients were treated in January 2024 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinqo) - 1
- Baricitinib (Olmiant) - 1
- Dupilumab (Dupixent) - 6
- Lebrikizumab (Ebglyss) - 0
- Omalizumab (Xolair) - 0
- Tralokinumab (Adtralza) - 0
- Upadacitinib (Rinvoq) - 0

Q2. How many patients were treated in January 2024 (or latest available month) by the Respiratory Medicine department with the following drugs:

- Benralizumab (Fasenra) - 4
- Dupilumab (Dupixent) - 6
- Mepolizumab (Nucala) - 17
- Omalizumab (Xolair) - 2
- Reslizumab (Cinqaero) - 0
- Tezepelumab (Tezspire) - 1